(EMAILWIRE.COM, November 26, 2018 ) Summary
According to the recently published report ‘Tyrosine Protein Kinase Fyn-Pipeline Review, H2 2018’; Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) pipeline Target constitutes close to 7 molecules.
Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)-Proto-oncogene tyrosine-protein kinase Fyn is an enzyme encoded by the FYN gene. It plays a role in many biological processes including regulation of cell growth and survival, cell adhesion, integrin-mediated signaling, cytoskeletal remodeling, cell motility, immune response and axon guidance. Inactive FYN is phosphorylated on its C-terminal tail within the catalytic domain. Following activation by PKA, the protein subsequently associates with PTK2/FAK1, allowing PTK2/FAK1 phosphorylation, activation and targeting to focal adhesions.
Get a Sample Report: http://www.reportsweb.com/inquiry&RW00012318852/sample
The report ‘Tyrosine Protein Kinase Fyn-Pipeline Review, H2 2018’ outlays comprehensive information on the Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase II, Preclinical and Discovery stages are 1, 1, 2, 2 and 1 respectively. Report covers products from therapy areas Oncology, Central Nervous System, Gastrointestinal, Metabolic Disorders, Respiratory, Cardiovascular, Hematological Disorders, Musculoskeletal Disorders and Women’s Health which include indications Alzheimer’s Disease, Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Peripheral T-Cell Lymphomas (PTCL), Systemic Mastocytosis, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Alcohol Addiction, Amyotrophic Lateral Sclerosis, Asthma, Bile Duct Cancer (Cholangiocarcinoma), Cancer Pain, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Chronic Obstructive Pulmonary Disease (COPD), Endometriosis, Epithelial Ovarian Cancer, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Gastrointestinal Stromal Tumor (GIST), Gliosarcoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hypereosinophilic Syndrome, Lymphangioleiomyomatosis, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Pancreatic Cancer, Myelodysplastic Syndrome, Myelofibrosis, Myeloid Metaplasia, Non-Small Cell Lung Cancer, Obesity, Oligodendroglioma, Ovarian Cancer, Parkinson’s Disease, Polycythemia Vera, Primary Progressive Multiple Sclerosis (PPMS), Psychosis, Pulmonary Arterial Hypertension, Recurrent Glioblastoma Multiforme (GBM), Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS) and Type 2 Diabetes.
Get Intresting Discount: http://www.reportsweb.com/inquiry&RW00012318852/discount
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
-The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)
-The report reviews Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
-The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
-The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
-The report reviews key players involved in Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
-The report assesses Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
-The report summarizes all the dormant and discontinued pipeline projects
-The report reviews latest news and deals related to Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics
Reasons to buy
-Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
-Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)
-Identify the use of drugs for target identification and drug repurposing
-Identify potential new clients or partners in the target demographic
-Develop strategic initiatives by understanding the focus areas of leading companies
-Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
-Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) development landscape
-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Get More Information : http://www.reportsweb.com/inquiry&RW00012318852/buying
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
